All In Biotech

Drug Trial Radar · NCT04381832

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 173 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

173

Actual

Start

Jul 7, 2020

Primary completion

Aug 30, 2024

Study completion Aug 30, 2024

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
May 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Conditions

  • Prostatic Neoplasms, Castration-Resistant
  • Androgen-Resistant Prostatic Neoplasms
  • Castration Resistant Prostatic Neoplasms
  • Prostatic Cancer, Castration-Resistant

Interventions

  • EtrumadenantDrug

    Etrumadenant is an A2aR and A2bR antagonist

  • ZimberelimabDrug

    Zimberelimab is an anti-PD-1 antibody

  • QuemliclustatDrug

    Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.

  • EnzalutamideDrug

    Enzalutamide is an androgen receptor inhibitor

  • DocetaxelDrug

    Docetaxel is type of chemotherapy

  • SGDrug

    Sacituzumab govitecan is an antibody-drug conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) in Stage 1 and 2Time frame: From study enrolment until participant discontinuation, or first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 3-5 years)
  2. Incidence and Severity of AEs and Serious Adverse Events (SAEs) in Stage 1Time frame: From first dose date to 90 days after the last dose (approximately 1.5 years)

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope & Innovation

    Cerritos, California

  • The University of California, Los Angeles

    Encino, California

  • The University of California, Irvine Medical Center

    Orange, California

  • Florida Cancer Specialists South

    Sarasota, Florida

  • Florida Cancer Specialists North

    St. Petersburg, Florida

  • Florida Cancer Specialists Panhandle

    Tallahassee, Florida

  • Florida Cancer Specialists East

    West Palm Beach, Florida

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • Affinity Health Hope & Healing Cancer Services

    Hinsdale, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • New York University, Langone Health

    New York, New York

  • Wilmot Cancer Institute Oncology, University of Rochester

    Rochester, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Tennessee Oncology - Chattanooga

    Chattanooga, Tennessee

  • Tennessee Oncology - Nashville

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Medical Oncology Associates, PS (dba Summit Cancer Centers)

    Spokane, Washington

  • Juravinski Cancer Center

    Hamilton, Ontario, Canada

  • Centre hospitalier de l'Université de Montréal (CHUM) Centre de Recherche

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.